ArticleExperimental hematology & oncology2026
Matrix stiffness induces Ca
Article in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Alterations in extracellular matrix (ECM) architecture and stiffness are hallmarks of aggressive pancreatic cancer progression. However, the mechanisms by which ECM biomechanical properties regulate malignant biological behavior remain unknown. Here, we reveal that calmodulin-dependent protein kinase doublecortin-like kinase 1 (DCLK1) integrates biomechanical signaling and promotes pancreatic cancer cell progression. DCLK1 expression and activation are selectively induced under conditions of high biomechanical stress mediated through the piezo-type mechanosensitive ion channel component 1 (PIEZO1)/calcium/hippocalcin-like protein 1 (HPCAL1) pathway. Consistently, in solid tumor experiments, DCLK1 overexpression under low stiffness conditions facilitates rapid tumor progression and chemoresistance, whereas using calcium inhibitors can partially reverse the adverse effects of DCLK1 overexpression. Conversely, under high stiffness conditions, DCLK1 knockdown inhibits tumor growth and enhances chemosensitivity but attenuates the sensitizing effect of combined calcium inhibitor treatment on chemotherapy efficacy. Mechanistically, DCLK1 interacts with phosphatidylinositol-4-phosphate 5-kinase type 1 alpha (PIP5K1A) by inhibiting its threonine phosphorylation, thereby facilitating PIP5K1A membrane localization. This activates the downstream phosphatidylinositol 3-kinase-protein kinase B (PI3K-AKT) signaling pathway, promoting cancer cell proliferation and chemoresistance. Collectively, these findings establish DCLK1 functions as a context-specific amplifier, exacerbating aggressive tumor progression and chemotherapy resistance in pancreatic cancer. Targeting the calcium/DCLK1 signaling axis may therefore enhance the efficacy of adjuvant therapies in pancreatic cancer.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.